ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

DA

Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital takes part in 4 sessions at ESMO 2026 in Madrid. Its work spans treatment and response assessment across several cancers. It includes an early study of a docetaxel-based drug designed to target integrins, and bone scans in breast cancer that has spread to bone.

OrganizationESMO 2026 Attendance
DA
Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Ankara, Türkiye
Cancer centre & hospital
Oncology training and research hospital in Ankara, Türkiye.
Poster
Fri Oct 23
13:00–15:00
First-in-human phase Ia/Ib study of RS-0139, an integrin-targeted docetaxel prodrug, in advanced solid tumors
ePoster session 6
Gastrointestinal cancersGynaecological cancersLung & thoracic cancersSarcoma, CNS, head & neck and rare cancersGenitourinary cancers
Poster
Fri Oct 23
13:00–15:00
Treatment response and clinical outcomes of tyrosine kinase inhibitors in metastatic differentiated thyroid cancers
ePoster session 22
Sarcoma, CNS, head & neck and rare cancers

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

Tell us what you sell and we’ll find the people at Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction